For example, in a randomized phase III trial of combination chemoimmunotherapy (dacarbazine, cisplatin, and interferon-alpha-2b) with or without IL-2 as adjuvant therapy, the results did not show a significant improvement in progression-free survival or the treatment response rate in patients with metastatic melanoma [19]. The gene discussed is IFNA2; the disease is metastatic melanoma.